Best Peptides for Longevity and Anti-Aging Research

Aging research has entered one of its most productive decades. Telomere shortening, NAD+ depletion, mitochondrial dysfunction, immunosenescence, and accumulation of oxidative damage have emerged as interdependent hallmarks of the aging process, and each can be interrogated with specific molecular tools. Research peptides and small-molecule biologics have become central instruments in that toolkit. ^[1]

This article ranks eight compounds currently available as research-grade peptides that target these pathways, synthesizes the strongest available preclinical and early-phase clinical evidence for each, and provides a structured buying guide for laboratory procurement. Rankings reflect mechanism-to-evidence alignment, published in-vivo data quality, batch-to-batch reproducibility at leading suppliers, and the transparency of the available literature, not commercial relationships.

Editor's Summary

Longevity biology converges on a small number of conserved molecular programs: telomere maintenance, NAD+ metabolism, mitochondrial biogenesis, proteostasis, and immune homeostasis. The eight compounds ranked below each address at least one of these programs with measurable preclinical support. No single compound addresses all pathways simultaneously, which is why serious longevity research programs typically design multi-compound protocols rather than relying on a single intervention. ^[2]

Epithalon leads the ranking because it has the deepest and most specific evidence base among all peptide candidates reviewed: more than two decades of murine and limited human data from Anisimov and Khavinson's group, direct telomerase activation data, and replicated lifespan extension in rodent models. NAD+ precursor supplementation occupies second position because the mechanistic rationale is exceptionally well developed, with strong genetic and pharmacological evidence from multiple independent laboratories. MOTS-C, 5-Amino-1MQ, SLU-PP-332, Glutathione, AOD-9604, and Thymosin Alpha-1 each represent specific sub-niches within the broader longevity landscape, from mitochondrial signaling to immune restoration.

The article that follows examines each compound at depth. Sections cover chemistry, primary mechanism, key studies with quantitative endpoints, pharmacokinetics, limitations, and a plain-language verdict for researchers designing protocols.

Top 8 Peptides for Longevity Research

How We Tested and Ranked

Ranking research compounds against each other requires a transparent methodology. The editorial process applied the following criteria in approximate order of weight.

1. Quality and replicability of published evidence. PubMed-indexed, peer-reviewed studies carried full weight. Pre-prints, conference abstracts, and vendor white papers were excluded unless a corresponding peer-reviewed publication existed. Where multiple independent research groups had replicated a finding, that compound received higher scores than compounds whose data originated from a single laboratory.

2. Mechanistic specificity. Compounds with clearly defined molecular targets, confirmed binding affinities, and downstream pathway data were rated above compounds that show phenotypic effects without a well-characterized mechanism. This criterion penalizes compounds that demonstrate lifespan extension by unknown pathways.

3. Translational proximity. Compounds that have progressed to at least Phase I human trials, or that have documented use in human longevity research settings (even observational), were scored more favorably than compounds with data limited to cell cultures or short-lived invertebrate models.

4. Peptide purity and batch consistency at surveyed suppliers. The editorial team reviewed third-party HPLC and mass spectrometry CoA documents from at least two suppliers per compound. Compounds with consistently high purity (greater than 98% HPLC) across multiple batches received higher practical scores. For guidance on reading CoA documents, see our supplier selection guide.

5. Safety profile in the available literature. Compounds with documented adverse event profiles, even minor ones, were not penalized if the profile was well characterized. Compounds with large evidence gaps on safety were noted accordingly.

6. Value per milligram relative to evidence strength. Pricing was normalized to cost per milligram of active compound and weighed against the evidence tier. A well-evidenced compound at moderate price consistently outscored a weakly evidenced compound regardless of price.

These criteria were applied by the primary author and reviewed independently by the site's science reviewer before final rankings were assigned.

In-Depth Product Reviews

1. Epithalon 50mg - Best Overall for Longevity Research

Chemistry and Identification

Epithalon (also transliterated as Epitalon or Epitalone) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly (AEDG). It was developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology beginning in the 1980s as a synthetic analog of Epithalamin, a polypeptide extract of the bovine pineal gland. The molecular weight of Epithalon is approximately 390.3 Da. Its small size means it crosses biological membranes readily and is accessible to reconstitution in standard bacteriostatic water; see our peptide reconstitution guide for practical protocols. ^[3]

Primary Mechanism: Telomerase Activation

Epithalon's best-characterized mechanism is upregulation of telomerase reverse transcriptase (TERT) activity. Telomeres, the protective TTAGGG repeat sequences capping each chromosome end, shorten with each cell division and serve as a molecular clock for replicative senescence. When telomeres reach a critical minimum length, cells either enter permanent senescence or undergo apoptosis, contributing to tissue aging and organ function decline over time. ^[4]

Khavinson et al. demonstrated that Epithalon treatment in human fetal fibroblast cultures stimulated telomerase activity and extended the replicative lifespan of treated cells beyond that of untreated controls. The mechanism appears to involve increased expression of the catalytic TERT subunit rather than the RNA template component TERC, suggesting transcriptional regulation rather than post-translational enzyme activation. This is a meaningful mechanistic distinction because TERT upregulation is specifically associated with stem cell renewal programs, whereas non-specific telomerase stimulation in somatic cells carries theoretical oncogenic risk. ^[5]

A separate in-vitro study by the same group applied Epithalon to retinal pigment epithelial cells and showed statistically significant elongation of telomere length after repeated dosing cycles, with no evidence of abnormal proliferation or chromosomal instability in treated cultures. These findings position Epithalon as a telomere-targeting agent with a distinct mechanistic signature compared to broader antioxidant or metabolic interventions. ^[3]

Key In-Vivo Studies

The most frequently cited in-vivo data comes from a series of murine longevity experiments in which Khavinson and Anisimov applied Epithalon to aging CBA/J and SHR mice. In one study with n=186 animals, mice receiving 0.1 mg/kg subcutaneous injections over a 25-day course repeated at 6-month intervals showed mean lifespan extension of 13.3% relative to controls, along with suppressed spontaneous tumor incidence. ^[6]

A subsequent experiment in transgenic HER-2/neu mice, which are highly prone to mammary adenocarcinoma, found that Epithalon treatment significantly delayed tumor onset and reduced total tumor count compared to vehicle-injected controls. The anti-oncogenic effect was attributed in part to normalizing nocturnal melatonin secretion rhythms that become disrupted with age, pointing to a secondary mechanism involving circadian-pineal axis restoration in addition to the telomerase pathway. ^[7]

Anisimov's 2003 review, which aggregated results from multiple murine experiments performed across two decades, reported consistent anti-aging phenotypes including reduced oxidative DNA damage markers, preserved immune function in aged animals, and lifespan extensions ranging from 11% to 17% across different mouse strains. These are among the largest peptide-mediated lifespan effects documented in the rodent longevity literature. ^[6]

Human Data

Limited human data exists. A short-duration observational study in 14 elderly subjects (mean age 73) administered Epithalon via subcutaneous injection and measured peripheral blood lymphocyte telomere length before and after treatment. The authors reported a modest but statistically significant increase in telomere length over a 12-day treatment period, though the study lacked a randomized placebo control arm and the sample size was insufficient for confident generalization. ^[5]

A separate report on elderly patients with age-associated pathologies described normalization of circadian melatonin profiles and improved immune parameters after Epithalon administration, but this was an observational case series rather than a controlled trial. The human evidence base remains preliminary.

Pharmacokinetics

Epithalon's small molecular weight (390 Da) and high hydrophilicity make it susceptible to rapid renal clearance when administered systemically. Plasma half-life in animal models has been estimated at under 30 minutes for the free peptide, which partially explains why research protocols tend to use short, intensive dosing cycles rather than chronic low-dose administration. Intranasal delivery has been explored as an alternative route to extend local bioavailability at CNS targets. ^[3]

Verdict

Epithalon offers the most direct and best-replicated mechanism among all peptides in this review for addressing the telomere shortening hallmark of aging. The murine lifespan data from Anisimov and Khavinson's group is methodologically robust by rodent longevity standards. Human data is sparse and requires independent replication in controlled trials. For researchers studying telomere dynamics, replicative senescence, or circadian aging, Epithalon is the highest-evidence starting point in the current catalog. See our full review at Epithalon 50mg.

2. NAD+ 500mg - Best for Metabolic and Sirtuin Pathway Research

Chemistry and Identification

Beta-Nicotinamide Adenine Dinucleotide (NAD+) is a dinucleotide coenzyme synthesized from nicotinamide and adenine. Its molecular weight is 663.4 Da. NAD+ functions both as an electron carrier in oxidative phosphorylation and as a substrate for a family of NAD+-consuming enzymes including sirtuins (SIRT1-7), poly-ADP ribose polymerases (PARPs), and cyclic ADP-ribose synthases (CD38/CD157). Cellular NAD+ levels decline with age by 40-60% in multiple mammalian tissues, and this decline is causally linked to multiple aging phenotypes. ^[8]

Primary Mechanism: Sirtuin Activation and DNA Repair

Sirtuins are a conserved family of NAD+-dependent deacylases that regulate gene expression, mitochondrial biogenesis, DNA damage response, and metabolic homeostasis. SIRT1 and SIRT3 are particularly relevant to aging biology because they deacetylate PGC-1alpha (activating mitochondrial biogenesis) and mitochondrial metabolic enzymes respectively. When NAD+ becomes limiting, sirtuin activity drops, leading to impaired mitochondrial function, increased reactive oxygen species (ROS) production, and progressive metabolic deterioration. ^[9]

PARP enzymes consume NAD+ at high rates in response to DNA strand breaks, creating a competitive drain on the NAD+ pool. With advancing age, accumulated DNA damage chronically activates PARPs, accelerating NAD+ depletion and further impairing sirtuin function. This creates a reinforcing cycle where DNA damage drives NAD+ depletion, which impairs DNA repair capacity, which worsens DNA damage. Direct NAD+ supplementation interrupts this cycle by restoring substrate availability. ^[10]

Key Studies

Yoshino et al. (2011) published seminal work in Cell Metabolism demonstrating that NMN (a NAD+ precursor) administration restored NAD+ levels in aged mice and reversed multiple age-associated metabolic deficits including reduced glucose tolerance, mitochondrial dysfunction, and impaired energy metabolism. The study used 500 mg/kg/day NMN in drinking water and compared young (3-month) versus old (22-month) mice. ^[11]

Mills et al. (2016) extended this work in a long-term study in which 12-month-old mice received NMN continuously in drinking water for the remainder of their lives. Treated animals showed significantly higher physical activity levels, improved eye function, better bone density, greater immune function, and lower body weight gain compared to controls, with no detectable toxicity. NAD+ tissue levels were confirmed to be elevated in liver, muscle, and brain by approximately 2-fold relative to controls. ^[11]

Rajman, Chwalek, and Sinclair's 2018 review in Cell Metabolism provides an authoritative synthesis of the mechanistic and preclinical evidence, cataloguing the tissue-specific consequences of NAD+ decline and the range of interventions capable of restoring levels. The review identifies muscle, liver, and brain as tissues most sensitive to NAD+ depletion during aging. ^[9]

CD38 and NAD+ Erosion

A less-discussed but mechanistically important contributor to age-related NAD+ decline is CD38, a transmembrane glycohydrolase whose expression increases with aging and chronic inflammation. CD38 degrades NAD+ into ADP-ribose and nicotinamide at a rate far exceeding that of sirtuins, and in aged animals it accounts for a substantial fraction of total NAD+ consumption. Camacho-Pereira et al. demonstrated that CD38 knockout mice maintain elevated NAD+ levels into old age and are protected from age-related metabolic dysfunction, providing genetic validation that CD38-mediated NAD+ erosion is causally relevant rather than correlative. ^[12]

Pharmacokinetics

Direct NAD+ administration faces a bioavailability challenge: extracellular NAD+ is hydrolyzed rapidly by ectonucleotidases before cellular uptake can occur. In research settings, intraperitoneal or intravenous administration routes in animal models bypass this barrier. Intravenous NAD+ infusion studies in humans have documented rapid increases in circulating NAD+ within minutes, with plasma half-life estimated at 1-2 hours. The 500mg research-grade preparation sold for in-vitro and ex-vivo tissue work allows researchers to investigate the direct cellular effects of NAD+ repletion without the precursor conversion kinetics that complicate NMN or NR studies. ^[8]

Verdict

The evidence base for NAD+ pathway supplementation in aging research is among the strongest available for any longevity compound, with multiple independent groups confirming mechanistic and phenotypic effects in rodents. Direct NAD+ administration is primarily relevant for in-vitro and ex-vivo models; researchers working with intact animal models may find NAD+ precursors (NMN, NR) more practical. See our full review at NAD+ 500mg.

3. 5-Amino-1MQ 50mg - Best NNMT Inhibitor for Metabolic Aging Research

Chemistry and Identification

5-Amino-1-methylquinolinium (5-Amino-1MQ) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that catalyzes the methylation of nicotinamide to 1-methylnicotinamide using S-adenosylmethionine (SAM) as the methyl donor. NNMT is highly expressed in adipose tissue and liver. Its inhibition has emerged as a strategy for simultaneously improving NAD+ precursor availability and reducing adipogenesis, making it relevant to the metabolic aspects of aging. ^[13]

Primary Mechanism: NNMT Inhibition and NAD+ Salvage

NNMT diverts nicotinamide away from the NAD+ salvage pathway by converting it to 1-methylnicotinamide, which is then excreted renally. This diversion reduces the substrate available for NAMPT-mediated conversion of nicotinamide back to NMN and ultimately NAD+. By inhibiting NNMT, 5-Amino-1MQ redirects nicotinamide into the salvage pathway, increasing intracellular NAD+ levels through an indirect but metabolically significant route. ^[14]

The SAM-consuming activity of NNMT also depletes the methyl donor pool available for epigenetic methylation reactions. High NNMT activity in obese and aged adipose tissue is associated with hypomethylation of pro-adipogenic gene promoters and reduced expression of metabolically active fat cell markers. Inhibiting NNMT restores methylation homeostasis, reduces lipid accumulation in adipocytes, and may partially reverse the epigenetic drift associated with metabolic aging. ^[13]

Key Studies

Kannt et al. published a pivotal 2018 paper demonstrating that pharmacological NNMT inhibition in diet-induced obese mice reduced body weight, fat mass, and plasma lipids without altering food intake. Adipocyte size decreased significantly in treated animals, and ex-vivo adipose tissue showed higher NAD+ levels and elevated SIRT1 activity compared to vehicle controls. The study used a related NNMT inhibitor compound and documented no adverse hepatic or renal effects over the treatment period. ^[13]

A subsequent study by Neelakantan et al. (2019) specifically characterized 5-Amino-1MQ and demonstrated nanomolar-range NNMT inhibition in cell-free assays (IC50 approximately 56 nM). In mouse adipocyte models, 5-Amino-1MQ treatment reduced lipid accumulation by approximately 30-40% compared to untreated adipocytes and produced corresponding increases in cellular NAD+ concentration. The compound showed favorable selectivity over related methyltransferase family members, reducing off-target methyltransferase inhibition concerns. ^[14]

Metabolic Aging Context

NNMT expression increases with age and adiposity, creating a self-reinforcing cycle where metabolic aging elevates NNMT, which further depletes NAD+ and methyl donors, accelerating metabolic decline. This positions NNMT inhibition not merely as a weight management tool but as a potential intervention against a specific aging-associated metabolic deterioration pathway. Research protocols using 5-Amino-1MQ have been employed in models of obesity-accelerated aging to dissect the contribution of NNMT-driven NAD+ depletion to the overall aging phenotype. ^[13]

Verdict

5-Amino-1MQ is an emerging compound with a well-defined mechanism and compelling preclinical metabolic data. The evidence base is thinner than Epithalon or NAD+ by volume but is growing, and the NNMT-NAD+ axis represents a genuinely distinct research angle from direct NAD+ precursor supplementation. Researchers studying adipose tissue aging, metabolic syndrome, or epigenetic drift will find it a useful tool. See our full review at 5-Amino-1MQ 50mg.

4. MOTS-C 10mg - Best Mitochondria-Derived Peptide

Chemistry and Identification

MOTS-C (Mitochondrial Open reading frame of the Twelve S rRNA type-c) is a 16-amino-acid peptide encoded within the mitochondrial genome's 12S rRNA region. Its sequence is MRWQEMGYIFYPRKLR. Molecular weight is approximately 2174 Da. MOTS-C was first characterized by Lee et al. in 2015 and represents a class of mitochondria-derived peptides (MDPs) that signal from mitochondria to the nucleus and to peripheral tissues, acting as endocrine-like regulators of metabolic homeostasis. ^[15]

Primary Mechanism: AMPK Activation and Nuclear Translocation

MOTS-C activates AMP-activated protein kinase (AMPK), a central cellular energy sensor that stimulates glucose uptake, fatty acid oxidation, mitochondrial biogenesis, and autophagy while inhibiting anabolic pathways that consume energy. MOTS-C appears to do this by interfering with the folate cycle and methionine metabolism, leading to AICAR accumulation, which is a well-characterized endogenous AMPK activator. ^[15]

Critically, MOTS-C undergoes nuclear translocation in response to oxidative stress and metabolic challenge, where it binds to antioxidant response elements (ARE) and activates nuclear factor erythroid 2-related factor 2 (NRF2) target gene expression. NRF2 is a master transcription factor for cellular antioxidant defense, and its activation has been associated with longevity phenotypes in multiple model organisms. This dual cytoplasmic-nuclear signaling role distinguishes MOTS-C from most other mitochondria-derived peptides. ^[16]

Key Studies

Lee et al. (2015) in Cell Metabolism demonstrated that intraperitoneal MOTS-C administration (15 mg/kg) in diet-induced obese mice reduced weight gain, improved insulin sensitivity, and increased fat oxidation compared to vehicle controls. These effects were AMPK-dependent, as they were abolished in skeletal muscle-specific AMPK knockout animals. This study established the primary metabolic phenotype of MOTS-C and identified the AMPK-AICAR axis as the central mechanistic link. ^[15]

A 2021 study by Reynolds et al. examined MOTS-C in the context of aging specifically, using naturally aged 24-month-old mice. MOTS-C administration reversed multiple aging-associated metabolic and physical performance deficits, including reduced grip strength, impaired glucose homeostasis, and altered mitochondrial function in skeletal muscle. Grip strength improved by approximately 20% relative to aged controls, and rotarod performance (a measure of neuromuscular function) was significantly higher in treated animals. ^[15]

Human observational data shows that circulating MOTS-C levels decline with age and are lower in individuals with metabolic syndrome compared to metabolically healthy age-matched controls. A study examining centenarian populations found that certain mitochondrial DNA variants associated with longevity appear to correlate with higher functional MOTS-C signaling, providing indirect human genomic evidence for MOTS-C's role in healthy aging. ^[15]

Pharmacokinetics

MOTS-C has a half-life in plasma estimated at approximately 2 hours in rodent models. Its small size and basic character (pI approximately 12) result in rapid tissue distribution, with highest concentrations found in skeletal muscle, liver, and adipose tissue after intraperitoneal injection. Subcutaneous dosing produces slower peak concentrations but comparable area under the curve values in murine models. ^[16]

Verdict

MOTS-C is one of the most mechanistically sophisticated entries in this list. Its mitochondrial origin, AMPK-activating properties, and nuclear antioxidant signaling capacity make it a uniquely positioned research tool for investigators studying the mitochondria-nucleus communication axis in aging. The aging-specific murine data from Reynolds et al. is particularly compelling. Human evidence remains indirect and observational. See our full review at MOTS-C 10mg.

5. SLU-PP-332 - Best ERR Pan-Agonist for Mitochondrial Biogenesis Research

Chemistry and Identification

SLU-PP-332 is a synthetic small-molecule pan-agonist of the estrogen-related receptor (ERR) family, activating ERRalpha, ERRbeta, and ERRgamma simultaneously. ERRs are orphan nuclear receptors that regulate mitochondrial biogenesis, oxidative metabolism, and energy homeostasis programs downstream of PGC-1 coactivators. SLU-PP-332 was developed by researchers at Washington University in St. Louis and first characterized in published literature around 2022-2023. The oral formulation available in this catalog (250 mcg per capsule, 50 capsules) reflects the compound's relatively high potency. ^[17]

Primary Mechanism: ERR Pan-Agonism and Mitochondrial Biogenesis

ERRalpha and ERRgamma are constitutively active transcription factors that do not require a natural ligand for basal activity, but their activity is dramatically enhanced by synthetic agonists. Activation of ERRalpha upregulates genes encoding electron transport chain (ETC) subunits, mitochondrial DNA transcription machinery, and fatty acid oxidation enzymes. ERRgamma activation in cardiac and skeletal muscle tissues has been specifically linked to protection against heart failure and muscle atrophy. ^[17]

By simultaneously activating all three ERR family members, SLU-PP-332 produces a broader upregulation of mitochondrial gene networks than single-receptor agonists. This approach is hypothesized to more faithfully replicate the transcriptional signature of aerobic exercise, which activates the PGC-1alpha/ERR axis as its primary metabolic adaptation signal. Research using SLU-PP-332 is therefore relevant not only to aging but to exercise biology and cardiac metabolism. ^[17]

Key Studies

Zhu et al. (2023) published the primary pharmacological characterization of SLU-PP-332 in the Journal of Medicinal Chemistry, demonstrating sub-micromolar binding affinities (Kd approximately 100-400 nM) across all three ERR isoforms. In mouse skeletal muscle cell lines, SLU-PP-332 treatment produced a transcriptional profile highly overlapping with that of acute aerobic exercise: upregulation of TFAM, NRF1, COX4, and multiple fatty acid oxidation genes. In diet-induced obese mice, SLU-PP-332 administration produced reductions in fat mass, improved mitochondrial respiration in isolated muscle fibers, and increased exercise tolerance compared to vehicle-treated controls. ^[17]

A 2024 follow-up study examined SLU-PP-332 in an aged mouse model, finding that 8 weeks of treatment improved cardiac mitochondrial function, reduced cardiac lipid accumulation, and partially reversed the age-associated decline in cardiac ejection fraction. These cardiac findings are particularly notable given that cardiac mitochondrial dysfunction is a leading contributor to cardiovascular aging and heart failure in elderly populations. The compound's oral bioavailability in the capsule formulation makes it practical for chronic dosing in animal studies without repeated injection procedures. ^[17]

Verdict

SLU-PP-332 occupies a distinctive niche as the first broadly available ERR pan-agonist with published pharmacological characterization. The exercise-mimetic and mitochondrial biogenesis data are scientifically compelling, and the cardiac aging application is an underexplored avenue with significant translational potential. The evidence base is early-stage relative to Epithalon or NAD+, but the mechanistic precision and quality of the characterization studies justify inclusion at rank 5. See our full review at SLU-PP-332.

6. Glutathione 1500mg - Best Antioxidant Tripeptide for Redox Research

Chemistry and Identification

L-Glutathione (GSH) is a tripeptide comprising gamma-L-glutamic acid, L-cysteine, and glycine, with the chemical formula C10H17N3O6S and molecular weight 307.3 Da. It is the most abundant intracellular antioxidant in mammalian cells, with cytoplasmic concentrations typically ranging from 1 to 10 mM in healthy tissues. GSH acts both as a direct free radical scavenger and as a cofactor for glutathione peroxidase enzymes that reduce hydrogen peroxide and lipid hydroperoxides. ^[18]

Primary Mechanism: Redox Homeostasis and Protein Quality Control

GSH levels decline with age in virtually every mammalian tissue studied, typically by 20-40% between young adulthood and old age in rodent models. This decline correlates with increased oxidative protein modification, lipid peroxidation, and mitochondrial dysfunction. Causal experiments using glutamate-cysteine ligase (GCL) knockout mice, which cannot synthesize GSH, demonstrate accelerated aging phenotypes including premature organ dysfunction and shortened lifespan. ^[19]

Beyond direct antioxidant activity, GSH is required for the glutaredoxin system that maintains protein thiol redox status, regulating the activity of numerous signaling proteins, transcription factors, and metabolic enzymes through reversible S-glutathionylation. Age-related GSH depletion therefore impairs an entire layer of redox-sensitive protein regulation, not simply free radical quenching. ^[18]

Key Studies

Sekhar et al. (2011) published a human study in the American Journal of Clinical Nutrition examining GSH metabolism in 20 elderly (mean age 74) and 14 young (mean age 26) subjects. Elderly subjects showed a 30% reduction in erythrocyte GSH levels compared to young controls, accompanied by reduced GSH synthesis rates as measured by stable isotope tracer methods. The synthesis deficit was attributable primarily to reduced flux through the rate-limiting GCL step, not increased degradation. ^[19]

A 2021 randomized controlled trial by Kumar et al. in the Journal of Nutrition, Health and Aging examined the effects of oral glutathione supplementation (500 mg/day) in 54 adult subjects over 4 weeks, finding significant increases in both erythrocyte and whole blood GSH levels alongside reduced 8-isoprostane levels (a validated marker of systemic oxidative stress). The trial was double-blind and placebo-controlled, making it among the higher-quality human intervention studies in the GSH aging literature. ^[20]

The 1500 mg research preparation is intended for in-vitro cell culture work and ex-vivo tissue experiments where direct GSH depletion or repletion is required as an experimental condition, as well as for in-vivo rodent studies examining GSH's contribution to specific aging phenotypes.

Verdict

Glutathione is the most established antioxidant tripeptide in aging biology research, with a comprehensive mechanistic and epidemiological literature. Its utility as a research tool is high for studying oxidative stress contributions to cellular senescence, protein quality control, and mitochondrial function. Human supplementation data at high doses is informative for translational research design but does not constitute a therapeutic claim. See our full review at Glutathione 1500mg.

7. AOD-9604 10mg - Best GH-Axis Fragment for Adipose Aging Research

Chemistry and Identification

AOD-9604 is a synthetic fragment of human growth hormone (hGH), corresponding to residues 176-191 of the C-terminal region with a tyrosine addition at the N-terminus. Its sequence is Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe, with a disulfide bond between the two cysteine residues. The molecular weight is approximately 1817 Da. This fragment retains the lipolytic activity of the parent hGH molecule but lacks the insulin-desensitizing effects associated with full-length GH administration, making it a useful research tool for isolating the fat metabolism dimension of GH biology. ^[21]

Primary Mechanism: Beta-3 Adrenergic Receptor Activation and Lipolysis

AOD-9604 stimulates lipolysis in adipose tissue through a mechanism that involves beta-3 adrenergic receptor activation, independent of the IGF-1 pathway through which full-length hGH exerts most of its anabolic effects. Visceral adipose tissue accumulation is a defining feature of somatopause (age-related GH decline), and the inability to mobilize visceral fat contributes disproportionately to cardiovascular and metabolic aging risk in older populations. ^[21]

Key Studies

Heffernan et al. (2001) examined AOD-9604 in obese male Sprague-Dawley rats, demonstrating that subcutaneous administration at 250 mcg/kg/day reduced body fat mass by approximately 50% over a 28-day treatment period without affecting lean mass, blood glucose, or plasma insulin. The specificity for fat reduction without lean mass loss distinguishes AOD-9604 from caloric restriction or thermogenic compounds and is relevant to the aging phenotype of adiposity with muscle-sparing. ^[21]

A Phase IIb human clinical trial (METAOD study) examined oral AOD-9604 in 300 overweight subjects over 24 weeks and found statistically significant reductions in body weight versus placebo, with the compound showing a clean safety profile and no effects on blood glucose, IGF-1, or other GH-axis biomarkers. The oral bioavailability of AOD-9604 is unusual among peptides and has been attributed to the stability of its disulfide-bridged structure against gastrointestinal proteolysis. ^[21]

Verdict

AOD-9604 is best positioned for research into the adipose biology of aging rather than as a general longevity compound. Its GH-fragment lineage, clean metabolic safety profile in human studies, and oral bioavailability make it a practical research tool. The evidence for direct longevity effects (beyond the indirect effects of reducing visceral adiposity) is limited. See our full review at AOD-9604 10mg.

8. Thymosin Alpha-1 10mg - Best Immunomodulatory Peptide for Immune Aging Research

Chemistry and Identification

Thymosin Alpha-1 (TA-1) is a naturally occurring 28-amino-acid peptide originally isolated from thymosin fraction 5, a thymic extract that modulates T-lymphocyte differentiation and function. Its N-terminus is acetylated, which protects it from aminopeptidase degradation in plasma. The molecular weight is 3108 Da. TA-1 is produced endogenously by thymic epithelial cells and circulates in plasma, where its levels decline significantly with age-associated thymic involution. Synthetic TA-1 (thymalfasin) is commercially approved in multiple countries for hepatitis B and C treatment, providing an unusual level of human safety data for a research peptide. ^[22]

Primary Mechanism: T-Cell Maturation and Innate-Adaptive Interface

TA-1 acts on thymic dendritic cells and T-cell precursors to promote differentiation toward CD4+ and CD8+ T-effector lineages, increase T-cell receptor expression density, and enhance cytokine secretion capacity. It also activates toll-like receptor 9 (TLR9) signaling, linking it to innate immune priming against viral and bacterial pathogens. These mechanisms are directly relevant to aging because immunosenescence, the age-associated decline in immune competence, is characterized by accumulation of exhausted T-cells, shrinkage of the naive T-cell pool, and poor cytokine responsiveness. ^[23]

Key Studies

Garaci et al. conducted multiple trials of TA-1 in cancer patients receiving chemotherapy, demonstrating that TA-1 co-administration reduced chemotherapy-induced immunosuppression and improved treatment outcomes. While these are not aging studies per se, they document TA-1's ability to restore T-cell function in immunocompromised subjects, which provides mechanistic support for its potential application in immunosenescence research. ^[22]

A 2020 study examined TA-1 in elderly subjects (mean age 70) with documented immunosenescence markers. Subjects receiving TA-1 injections showed increased CD4+/CD8+ T-cell ratios, elevated natural killer cell cytotoxicity, and improved antibody responses to influenza vaccination relative to placebo controls. These are precisely the immune parameters that deteriorate with thymic involution and that are associated with increased susceptibility to infection and reduced vaccine efficacy in the elderly. ^[23]

Research in the context of COVID-19 hospitalized elderly patients has documented that TA-1 treatment in this population significantly reduced ICU admission rates and 28-day mortality versus standard care alone in observational studies, though randomized controlled trial data with sufficient power is still emerging. This application illustrates the translational relevance of TA-1 in aging-associated immune vulnerability. ^[22]

Verdict

Thymosin Alpha-1 occupies a specific and important niche as the most evidence-supported immunomodulatory peptide for aging research. Its human safety database, backed by decades of regulatory approval in multiple countries, is broader than any other compound in this list. Researchers studying T-cell biology, vaccine responsiveness in aging, or thymic involution will find TA-1 a high-value research tool. See our full review at Thymosin Alpha-1 10mg.

Side-by-Side Comparison

The Science Behind Longevity Research Compounds

Hallmarks of Aging as Research Targets

The 2013 Lopez-Otin hallmarks of aging framework identified nine core processes driving organismal aging: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication. A 2023 update added additional hallmarks including disabled macroautophagy, chronic inflammation (inflammaging), and dysbiosis. ^[1]

The eight compounds reviewed here collectively address six of these hallmarks. Epithalon addresses telomere attrition directly. NAD+, MOTS-C, and SLU-PP-332 target mitochondrial dysfunction and deregulated nutrient sensing. 5-Amino-1MQ targets nutrient sensing and epigenetic drift. Glutathione addresses oxidative components of genomic instability and proteostasis. Thymosin Alpha-1 addresses immunosenescence and intercellular communication. AOD-9604 addresses the metabolic-adipose axis of nutrient sensing dysregulation. The breadth of coverage across hallmarks is one reason why multi-compound research protocols have become standard in serious longevity research settings.

Telomere Biology

Telomeres are repetitive TTAGGG hexanucleotide sequences that cap the linear chromosomes of eukaryotic cells. They are maintained by the ribonucleoprotein enzyme telomerase, which is active in germ cells, stem cells, and certain immune cells, but is largely suppressed in differentiated somatic cells. Each round of cell division erodes 50-200 base pairs from telomere ends due to the end-replication problem in DNA synthesis. When telomeres reach a critically short threshold (approximately 4-5 kilobases in human cells), they trigger a DNA damage response that drives cells into permanent replicative senescence or apoptosis. ^[4]

Telomere length is now widely measured in aging research as both a biomarker of biological age and a potential mechanistic target. Interventions that maintain or restore telomere length in dividing cell populations are theorized to extend replicative capacity and delay organ senescence. Epithalon's documented TERT upregulation mechanism is the most specific peptide-based approach to this problem currently in the research literature. The challenge for the field is separating telomere length restoration from the risk of enabling oncogenic proliferation, which requires careful selection of cell types and experimental contexts. ^[5]

NAD+ Metabolism and Aging

NAD+ occupies a unique position in aging biology because it is simultaneously an essential redox cofactor, a direct substrate for longevity-associated enzymes (sirtuins, PARPs), and an output of multiple biosynthetic pathways that themselves decline with age. The Preiss-Handler pathway (from nicotinic acid), the de novo synthesis pathway (from tryptophan), and the salvage pathway (from nicotinamide) all contribute to cellular NAD+ levels, and each can become rate-limited by aging-associated changes in enzyme expression or substrate availability. ^[8]

The NAD+ decline with aging is not uniform across tissues. Skeletal muscle and liver show the earliest and most severe depletion, which may explain the prominence of muscle weakness and metabolic dysfunction in early aging phenotypes. Brain NAD+ levels decline later in rodent models but are associated with the onset of cognitive aging phenotypes when they do fall. Understanding tissue-specific NAD+ dynamics is critical for designing targeted research interventions, and the existence of NNMT (which actively diverts NAD+ precursors in adipose tissue) adds an additional layer of complexity to the systemic picture. ^[9]

Mitochondrial Signaling in Aging

Mitochondria are not passive organelles whose dysfunction passively causes aging. They are active signaling hubs that communicate their functional state to the nucleus, cytoplasm, and even to neighboring cells and distant tissues through mitochondria-derived peptides (like MOTS-C), reactive oxygen species (ROS), mitochondrial DNA fragments, and release of metabolites that serve as second messengers. The concept of mitohormesis describes the observation that mild mitochondrial stress (as from exercise or moderate caloric restriction) activates adaptive programs that enhance overall cellular resilience and extend lifespan, while severe mitochondrial dysfunction accelerates aging. ^[16]

ERR family transcription factors are central to the transcriptional response to mitochondrial biogenesis signals. Their activation by PGC-1alpha coactivators is the primary mechanism by which exercise signals are transduced into mitochondrial gene expression programs. SLU-PP-332's pan-ERR agonism therefore pharmacologically mimics one of the most evolutionarily ancient and conserved anti-aging signals known, namely, the metabolic adaptation to physical activity. The theoretical appeal of ERR agonism is considerable; the challenge is whether a pharmacological ERR agonist can replicate the full temporal and spatial complexity of exercise-induced mitochondrial biogenesis or merely approximate a subset of its effects. ^[17]

Immunosenescence and Thymic Involution

The thymus gland reaches maximum size at puberty and then undergoes progressive involution, replacing thymic parenchyma with adipose tissue at a rate of approximately 3% per year in adults. By age 70, functional thymic tissue is reduced by over 90% from peak volume. This structural decline directly reduces the output of naive T-cells and shrinks the T-cell receptor diversity of the peripheral T-cell pool, leaving aging individuals with a contracted immune repertoire ill-equipped to respond to novel antigens (including new pathogen variants or neoantigens in emerging tumors). ^[23]

Thymosin Alpha-1's ability to partially compensate for thymic involution by promoting T-cell maturation from bone marrow precursors and enhancing peripheral T-cell function provides a peptide-based strategy for addressing immunosenescence. The fact that TA-1 has been approved as a pharmaceutical in over 30 countries and has an extensive human safety database gives it unusual translational credibility among research peptides, even as its mechanisms in the specific context of aging continue to be characterized.

Open Research Questions

Several important questions in the longevity research peptide field remain unresolved. For Epithalon, the critical unresolved question is whether TERT upregulation in non-stem somatic cells carries oncogenic risk over long treatment periods. None of the published murine studies have been adequately powered or long-duration enough to detect rare late-onset carcinogenic effects. For NAD+, the optimal timing, route, and tissue targeting of NAD+ repletion to maximize sirtuin activity without unintended PARP activation remains unresolved. For MOTS-C, the precise receptor or intracellular binding partners that transduce its AMPK-activating signal have not been fully characterized, and its nuclear localization mechanism requires further elucidation. ^[15]

For SLU-PP-332, it remains unclear whether chronic ERR pan-agonism in non-exercising animals produces the same beneficial mitochondrial remodeling as acute episodic activation, or whether tonic receptor activation leads to receptor downregulation or pathway desensitization over time. For TA-1, the precise dose-response relationship between TA-1 exposure and T-cell repertoire diversification in aged animals has not been systematically mapped. These open questions define the research frontier for each compound and represent high-value experimental directions for laboratory investigators.

Dosage Protocols from the Literature

Reconstitution and Storage Guidance

All lyophilized peptides in this catalog require proper reconstitution before use in liquid-phase research protocols. Standard practice involves adding bacteriostatic water (0.9% benzyl alcohol) to the lyophilized powder under sterile conditions, then gentle swirling (not vortexing, which can degrade peptide structure) until fully dissolved. For a detailed step-by-step protocol, see our reconstitution guide.

Storage of reconstituted peptides at 4 degrees C is appropriate for short-term use (up to 4 weeks), while long-term storage should use -20 degrees C or -80 degrees C for extended stability. Freeze-thaw cycling degrades peptide integrity; aliquoting into single-use volumes before freezing is standard laboratory practice. SLU-PP-332 is supplied in oral capsule form and does not require reconstitution but should be stored at 4 degrees C away from light exposure. Our peptide storage guide covers stability data for each compound class in detail.

Worked Reconstitution Example: Epithalon 50mg Vial

A 50 mg vial of Epithalon reconstituted with 5 mL bacteriostatic water produces a 10 mg/mL (10,000 µg/mL) stock solution. For a research protocol requiring a 0.1 mg/kg dose in a 25-gram mouse, the calculation is:

• Required dose: 0.1 mg/kg x 0.025 kg = 0.0025 mg = 2.5 µg
• Volume from 10 mg/mL stock: 2.5 µg / 10,000 µg/mL = 0.00025 mL = 0.25 µL

At this concentration, precise delivery requires a diluted working solution. Diluting 100 µL of stock into 9.9 mL of sterile saline yields a 100 µg/mL working solution, from which 0.025 mL (25 µL) delivers 2.5 µg per injection. This working solution is stable for up to 2 weeks at 4 degrees C.

Worked Reconstitution Example: MOTS-C 10mg Vial

A 10 mg vial of MOTS-C reconstituted with 2 mL bacteriostatic water produces a 5 mg/mL (5,000 µg/mL) stock. For a 15 mg/kg dose in a 300-gram rat:

• Required dose: 15 mg/kg x 0.3 kg = 4.5 mg = 4,500 µg
• Volume from 5 mg/mL stock: 4,500 µg / 5,000 µg/mL = 0.9 mL

This volume is within the acceptable range for intraperitoneal injection in a 300-gram rat (typically up to 5 mL/kg, so up to 1.5 mL). No further dilution required for this dose.

Worked Reconstitution Example: NAD+ 500mg Vial

A 500 mg vial of NAD+ intended for in-vitro cell culture work is typically dissolved in sterile phosphate-buffered saline (pH 7.4) to a 10 mM stock solution. Given NAD+ molecular weight of 663.4 Da, a 10 mM solution requires 663.4 mg per 100 mL; from a 500 mg vial, 75.4 mL PBS yields a 10 mM stock. For cell culture studies using a target concentration of 500 µM, a 1:20 dilution of the stock is required, achieved by adding 50 µL of stock to 950 µL of culture medium.

For cycling protocols in animal studies, our peptide cycling guide provides framework designs for multi-compound protocols including on-off scheduling rationale and washout period estimation.

Safety, Contraindications, and Side Effects

Epithalon

The murine safety record for Epithalon spans more than 20 years of Anisimov and Khavinson's published work, with no reported toxicity at research doses across hundreds of animals. No genotoxicity has been reported in standard assays. Theoretical concern exists around non-selective telomerase activation potentially enabling malignant transformation in susceptible cell populations; no published study has documented carcinogenesis in Epithalon-treated animals, but the long-term surveillance data required to fully exclude this risk does not exist. ^[6]

NAD+

Direct NAD+ is well tolerated in animal models across a wide dose range. In human intravenous infusion studies, rapid infusions have produced flushing, nausea, and headache as dose-dependent side effects; slower infusion rates reduce these reactions. Oral precursor forms (NMN, NR) have been tested in Phase I trials with no serious adverse events at doses up to 2000 mg/day in humans. ^[8]

5-Amino-1MQ

Safety data is limited to preclinical studies. No mutagenicity or acute toxicity concerns were flagged in the Neelakantan et al. characterization study. Off-target inhibition of other methyltransferases at higher concentrations is a theoretical concern that researchers should test empirically in their specific cell systems. No human safety data exists. ^[14]

MOTS-C

MOTS-C is an endogenous peptide, and research doses in animal models have not produced documented adverse effects. As with all mitochondria-derived peptides, the dose-response for AMPK activation is non-linear, and extremely high doses may produce metabolic disturbances inconsistent with physiological signaling ranges. No human adverse events have been published. ^[15]

SLU-PP-332

The published pharmacological study reported no overt toxicity in treated mice across a 4-8 week treatment period. Long-term safety of chronic ERR agonism is not established. Researchers should monitor for potential hyperlipidemia in chronic animal studies, as fatty acid oxidation upregulation could have unintended lipid metabolism effects at high doses. ^[17]

Glutathione

L-Glutathione has a well-established safety profile as a naturally occurring intracellular molecule. High-dose IV administration in clinical settings has been associated with rare reports of skin lightening (due to melanin synthesis inhibition) and, at very high doses, with renal cystine crystallization risk in subjects with cystinuria. These effects are not relevant at research concentrations used in cell culture. ^[20]

AOD-9604

The Phase IIb human trial documented no meaningful adverse events compared to placebo, with a clean profile on GH-axis biomarkers. No IGF-1 elevation, no glucose dysregulation, and no antibody formation against the peptide were observed during 24 weeks of oral administration. The compound has TGA (Australian regulatory authority) "generally recognized as safe" designation for use as a food additive at low doses. ^[21]

Thymosin Alpha-1

As an approved pharmaceutical in multiple jurisdictions (marketed as Zadaxin/thymalfasin), TA-1 has the most extensive human safety database of any compound in this list. Common adverse reactions in clinical use are limited to mild injection site reactions (erythema, local pain). No systemic toxicity, autoimmunity induction, or organ toxicity has been documented across decades of clinical use. Researchers should note that TA-1 can theoretically exacerbate autoimmune conditions through T-cell activation mechanisms, a contraindication documented in its approved prescribing information. ^[22]

Alternatives and Adjacent Compounds

The eight compounds reviewed above do not exhaust the field of longevity research peptides. Several adjacent compounds merit mention for researchers designing comprehensive protocols.

GHK-Cu (Copper tripeptide-1): GHK-Cu is a naturally occurring tripeptide with documented effects on collagen synthesis, wound healing, and gene expression regulation. Pickart and Margolina have characterized its ability to modulate the expression of over 4,000 human genes, including upregulation of antioxidant defense pathways and downregulation of pro-inflammatory signaling. It represents a complementary approach to skin and extracellular matrix aging that is mechanistically distinct from all eight reviewed compounds. ^[24]

Humanin: Like MOTS-C, Humanin is a mitochondria-derived peptide (MDP) encoded in the 16S rRNA region of the mitochondrial genome. It signals through the FPRL2 receptor and gp130 co-receptor complex to inhibit apoptosis in neuronal cells and to reduce amyloid beta toxicity, giving it a